Keryx Biopharmaceuticals Announces Zerenex(TM) (ferric citrate coordination complex) Meets All Primary and Key Secondary Endpoints in Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients With Elevated Serum Phosphorus and Iron Deficiency Anemia
Highly Statistically Significant Differences Observed in Serum Phosphorus, TSAT, Ferritin, Hemoglobin and FGF-23 versus Placebo
Conference Call to Be Held Today, November 5, 2013, at 8:30 am Eastern Time
Keryx Biopharmaceuticals, Inc. (KERX) today announced successful top-line results from its Phase 2 study of Zerenex(TM) (ferric citrate coordination complex) in non-dialysis dependent chronic kidney disease (NDD-CKD) patients with elevated serum phosphorus and iron deficiency anemia. In this study, Zerenex met both co-primary endpoints, described below, demonstrating highly statistically significant changes in serum phosphorus and transferrin saturation (TSAT) versus placebo over the 12-week treatment period.
- Published: 05 November 2013
- Written by Editor